ASCO 2016: Dr. Susan O’Brien where she discusses frontline data on Acalabrutinib in CLL

We are 8 weeks out from the 2016 annual meeting of the American Society of Hematology and realize that we have quite a few interviews from the ASCO and EHA meetings that have not yet been posted, so we’ll be posting twice a week until they are all out the door on the CLL Society's website.

If you have not yet participated in our Reader Poll to give us feedback about how we’re doing and what topics you would like to see covered in the future, please take 2 minutes and do so if you have time. You can access it here. q32016ask.questionpro.com/

We just posted an interview from ASCO 2016 with Dr. Susan O’Brien where she discusses frontline data on Acalabrutinib, a promising second-generation BTK inhibitor. You can access my article, the abstract and our interview here. cllsociety.org/2016/10/asco...

NEW Patient & Caregiver Support Meetings

Tuesday, October 18th at 6:30 PM at the Levine Cancer Institute in Charlotte, NC – the first meeting of a new CLL Patient & Caregiver Support and Education Group. Patients and family caregivers are welcome. Find out more about dates and registration here. cllsociety.org/docs/CLL%20P...

Tuesday, November 1st at 6:30 PM at the Moffitt McKinley Outpatient Center in Tampa, FL – the first meeting of a new CLL Patient & Caregiver Support and Education Group. Patients and family caregivers are welcome. You can find more information here! cllsociety.org/docs/Tampa%2...

If you’re aware of other CLL Patient Support Group meetings, let us know and we’ll post them.

Thanks. Stay strong

Brian

cllsociety.org

3 Replies

oldestnewest
  • This does look very hopeful, thanks for posting. How is Acalabrutinib pronounced and where has it come from?

  • Used to be ACP-196... Acerta Pharma... now owned by AstraZeneca... it will be starting the FDA approval process this winter...

    pronounced acala-brut-i-nib

    It is a second generation drug that targets the same pathway as ibrutinib, but with fewer side effects it is believed.

    ~chris

  • Very interesting short interview. Looking forward to seeing more information as it becomes available. rob